Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

被引：0
|
作者：
Seike, M. [1 ]
Inoue, A. [2 ]
Sugawara, S. [3 ]
Morita, S. [4 ]
Hosomi, Y. [5 ]
Ikeda, S. [6 ]
Watanabe, K. [7 ]
Takahashi, K. [8 ]
Fujita, Y. [9 ]
Harada, T. [10 ]
Minato, K. [11 ]
Takamura, K. [12 ]
Kobayashi, K. [13 ]
Nukiwa, T. [14 ]
机构：
[1] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan
[2] Tohoku Univ, Sch Med, Dept Palliat Med, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Pulm Med, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Biomed Stat & Bioinformat, Kyoto, Japan
[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[6] Cardiovasc & Resp Ctr, Div Resp Med, Yokohama, Kanagawa, Japan
[7] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[8] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan
[9] Asahikawa Med Ctr, Resp Med, Asahikawa, Hokkaido, Japan
[10] JCHO Hokkaido Hosp, Dept Pulm Med, Sapporo, Hokkaido, Japan
[11] Gunma Prefectural Canc Ctr, Dept Pulm Med, Ota, Japan
[12] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan
[13] Saitama Med Univ, Int Med Ctr, Dept Pulm Med, Saitama, Japan
[14] Tohoku Univ, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1382PD
引用
收藏
页码：496 / 496
页数：1
相关论文
共 50 条
  • [41] A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Han, Ji-Youn
    Lee, Soo-Hyun
    Yoo, Nam Jin
    Lee, Suk Hyung
    Moon, Yoon Joo
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1553 - 1560
  • [42] Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced NonSmall Cell Lung Cancer
    Zhao, H.
    Zhang, Z.
    Li, S.
    Fang, W.
    Ma, Y.
    Zhang, Y.
    Yang, Y.
    Luo, F.
    Huang, Y.
    Zhang, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S506 - S506
  • [43] AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC).
    Besse, Benjamin
    Felip, Enriqueta
    Clifford, Corinne
    Louie-Gao, Melinda
    Green, Jennifer
    Turner, Christopher D.
    Popat, Sanjay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
  • [45] A RANDOMISED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Yang, J. C-H.
    Park, K.
    Mok, T.
    Kang, J. H.
    Srimuninnimit, V.
    Lin, C. -C.
    Kim, D. -W.
    Tsai, C. -M.
    Orlando, M.
    Nair, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : E27 - E27
  • [46] A RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSQNSCLC)
    Yang, James C.
    Park, Keunchil
    Mok, Tony Shu Kam
    Kang, Jin Hyoung
    Srimuninnimit, Vichien
    Lin, Chia-Chi
    Kim, Dong-Wan
    Tsai, Chun-Ming
    Barraclough, Helen
    Altug, Sedat
    Orlando, Mauro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S288 - S288
  • [47] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
    Yang, James Chih-Hsin
    Kang, Jin Hyoung
    Mok, Tony
    Ahn, Myung-Ju
    Srimuninnimit, Vichien
    Lin, Chia-Chi
    Kim, Dong-Wan
    Tsai, Chun-Ming
    Barraclough, Helen
    Altug, Sedat
    Orlando, Mauro
    Park, Keunchil
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2219 - 2230
  • [48] A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations
    Tamiya, Akihiro
    Tamiya, Motohiro
    Nakatani, Akeshi
    Shiroyama, Talcayuki
    Kitai, Kanako
    Tsuji, Taisuke
    Morishita, Naoko
    Omachi, Naold
    Asami, Kazuhiro
    Okamoto, Norio
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Hiroshima, Tomonort
    Atagi, Shinji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Motohiro Tamiya
    Akihiro Tamiya
    Hiroyasu Kaneda
    Kazuhiko Nakagawa
    Kiyotaka Yoh
    Koichi Goto
    Hiroaki Okamoto
    Tsuneo Shimokawa
    Tetsuya Abe
    Hiroshi Tanaka
    Haruko Daga
    Koji Takeda
    Tomonori Hirashima
    Shinji Atagi
    [J]. Medical Oncology, 2016, 33
  • [50] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Yoh, Kiyotaka
    Goto, Koichi
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Abe, Tetsuya
    Tanaka, Hiroshi
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    [J]. MEDICAL ONCOLOGY, 2016, 33 (01) : 1 - 7
12345